HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Thoralf M. Sundt Hartzell V. Schaff Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, J. L. Articles by Schaff, H. V. Search for Related Content PubMed PubMed Citation Articles by Thompson, J. L. Articles by Schaff, H. V.

J Thorac Cardiovasc Surg 2007;134:359-365
© 2007 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Melagatran for thromboprophylaxis after mechanical valve implantation: Results in a heterotopic porcine model

^a Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn
^b Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn.

Received for publication October 24, 2006; revisions received January 2, 2007; accepted for publication January 17, 2007.

^_* Address for reprints: Hartzell V. Schaff, MD, Division of Cardiovascular Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905. (Email: schaff.hartzell{at}mayo.edu).

Objective: Melagatran, the active form of ximelagatran, is a novel, direct thrombin inhibitor that does not have a narrow therapeutic window regarding hemorrhagic and thromboembolic events. We aimed to determine whether melagatran would be effective in preventing thrombus formation on heterotopically placed mechanical heart valves.

Methods: A graft containing a bileaflet mechanical heart valve was implanted in the descending thoracic aorta of domestic swine. Two groups of 6 animals received daily subcutaneous injections of either melagatran (2.4 mg/kg, 3 times per day) or dalteparin (175 U/kg, 2 times per day) for 30 days. Four control animals received no anticoagulation therapy. Fecal HemoQuant and serum hemoglobin levels were recorded. Thirty days after the procedure, platelets were labeled with indium 111, the abdominal organs were inspected, and thrombi and platelets deposited on the valve were measured.

Results: Median thrombus burden on the valves was 0.4 mg (interquartile range, 0.15-5.45 mg) with melagatran, 0.5 mg (interquartile range, 0-14.5 mg) with dalteparin, and 168 mg (interquartile range, 32.5-665.75 mg) for controls (melagatran vs dalteparin and control; P = .04). Median platelet deposition on the valves was 0 (interquartile range, 0-8.9 x 10⁴) with melagatran, 49.9 x 10⁴ (interquartile range, 27.9 x 104-191.8 x 10⁴) with dalteparin, and 115.2 x 10⁴ (interquartile range, 9.6 x 10⁴-243 x 10⁴) for controls (melagatran vs dalteparin and control; P = .02). Melagatran did not increase the risk of thromboembolism or bleeding.

Conclusions: Thrombus and platelet accumulation on the prosthetic valves was decreased by melagatran and dalteparin. The use of melagatran or other related direct thrombin inhibitors warrants further study in prophylaxis of thromboembolism in patients with mechanical heart valves.

This article has been cited by other articles:

				S. H. McKellar, J. L. Thompson III, R. F. Garcia-Rinaldi, R. J. MacDonald, T. M. Sundt III, and H. V. Schaff Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine. J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 908 - 914. [Abstract] [Full Text] [PDF]